Clinical Trials Logo
  1. Home
  2. Mild Cognitive Impairment (MCI)
  3. NCT03448055

Nutritional Intervention With the Dietary Supplement, Immunocal® in MCI Patients: Promotion of Brain Health

Mild Cognitive Impairment (MCI) Clinical Trial

Official title:
Nutritional Intervention With the Cysteine-rich Whey Protein Isolate Dietary Supplement Immunocal® in MCI Patients: Promotion of Brain Health & Wellness During Aging and Oxidative Stress

Clinical Trial Summary

Alzheimer disease (AD) is a dementing illness characterized by progressive neuronal degeneration, gliosis, and the accumulation of intracellular inclusions and extracellular deposits of amyloid in discrete regions of the basal forebrain, hippocampus, and the association cortices. Mild cognitive impairment (MCI) refers to individuals with cognitive impairment (often memory loss) that fails to meet clinical criteria for AD or another dementing illness.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03448055
Study type Interventional
Source Immunotec Inc.
Contact
Status Recruiting
Phase N/A
Start date February 5, 2018
Completion date November 25, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT00934531 - Donepezil and the Risk of Falls in Seniors With Cognitive Impairment N/A
Withdrawn NCT05033912 - A Study of CST-2032 in Subjects With Cognitive Impairment Phase 1
Recruiting NCT02854033 - Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Completed NCT01902004 - Brain Aging and Treatment Response in Geriatric Depression Phase 4
Completed NCT01212692 - Effects of Mental Stimulation in Patients With Mild Cognitive Impairment Phase 2
Recruiting NCT00544791 - The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment Phase 2
Withdrawn NCT04055532 - Biomarkers in Neurodegenerative Diseases
Terminated NCT02180529 - The Effects of Methylphenidate on the Cognitive Function of Older People With Mild Cognitive Impairment N/A
Completed NCT05108922 - A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) Phase 3
Recruiting NCT05865340 - To Exam the Efficacy of Oral Health and Mediterranean Diet Interventions in Preventing Cognitive Decline Among Older Adults With Mild Cognitive Impairment N/A
Recruiting NCT06453941 - Yizhi Baduanjin for Patients With Cognitive Impairment N/A
Completed NCT06417034 - Hand Training Device For Cognitive Care N/A
Completed NCT02110043 - Modulation of Visual-Spatial Learning in Patients With Mild Cognitive Impairment (MCI) by tDCS N/A
Completed NCT01383161 - 18-Month Study of Memory Effects of Curcumin Phase 2
Completed NCT01299766 - Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment Phase 3
Withdrawn NCT05321498 - Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation Phase 2
Completed NCT04748666 - PST for Care Partners of Adults With Alzheimer's and Alzheimer'S-related Dementia N/A
Recruiting NCT03138018 - Aging Stereotypes and Prodromal Alzheimer's Disease N/A
Withdrawn NCT01891383 - Clinical Characteristics of Dementias That Occur Remotely After Traumatic Brain Injury in Retired Military Personnel
Completed NCT01231971 - Alzheimer's Disease Neuroimaging Initiative 2